Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01VLT
|
|||
| Former ID |
DNCL003350
|
|||
| Drug Name |
ASP8232
|
|||
| Indication | Diabetic macular edema [ICD-11: 9B71.02] | Phase 2 | [1] | |
| Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Phase 1 | [2] | ||
| Company |
Astellas
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Membrane copper amine oxidase (AOC3) | Target Info | Inhibitor | [1] |
| BioCyc | Phenylethylamine degradation I | |||
| Spermine and spermidine degradation I | ||||
| KEGG Pathway | Glycine, serine and threonine metabolism | |||
| Tyrosine metabolism | ||||
| Phenylalanine metabolism | ||||
| beta-Alanine metabolism | ||||
| Metabolic pathways | ||||
| Panther Pathway | Phenylethylamine degradation | |||
| Pathwhiz Pathway | Beta-Alanine Metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of Astellas Pharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.